Pediatric Nephrology

, 24:597 | Cite as

Remission of resistant MPGN type I with mycophenolate mofetil and steroids

  • Sudarsana De
  • Dana Al-Nabhani
  • Paul Thorner
  • Daniel Cattran
  • Tino D. Piscione
  • Christoph Licht
Brief Report

Abstract

Very few studies have been published on how to treat children with membranoproliferative glomerulonephritis type I (MPGN I), and as yet there is only one report on the use of mycophenolate mofetil (MMF) in children with MPGN I. We report a 12-year-old boy who presented with edema, hypertension, nephrotic range proteinuria, and microscopic hematuria following an upper respiratory tract infection. Laboratory tests revealed a serum creatinine of 90 µmol/l, albumin of 20 g/l, and a C3 of 0.11 g/l (normal range: 0.7–1.4). Renal biopsy showed the presence of MPGN I. Upon failure to induce remission with prednisone, we started the patient on MMF at 500 mg/day (300 mg/m2), increasing up to a final dose of 2 g/day (1200 mg/m2), with a MMF metabolite mycophenolic acid (MPA) target range of 2–5 mg/l. Prednisone was subsequently reduced to alternate day therapy and gradually weaned to 7.5 mg on alternate days over 9 months. Within 4 months of starting MMF therapy, there was significant improvement in serum creatinine (decrease from 156 to 64 µmol/l), serum albumin (increase from 23 to 40 g/l), and proteinuria (decrease from 13 g/day to 40 mg/day). Twelve months following the introduction of MMF into his therapeutic regimen, he remains in remission with no further relapses. In summary, this case suggests that there may be potential benefit for use of MMF in children with refractory MPGN I, which supports the rationale for prospectively evaluating MMF treatment in a treatment trial of refractory MPGN I.

Keywords

Membranoproliferative glomerulonephritis type I Mycophenolate mofetil Prednisone Proteinuria 

References

  1. 1.
    Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr (1992) Treatment of mesangiocapillary glomerulonephritis with alternate day prednisone—a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 6:123–130PubMedCrossRefGoogle Scholar
  2. 2.
    Levin A (1999) Management of membranoproliferative glomerulonephritis: Evidence-based recommendations. Kidney Int 55(Suppl 70):S41–S46CrossRefGoogle Scholar
  3. 3.
    Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A (2004) Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 19:3160–3164PubMedCrossRefGoogle Scholar
  4. 4.
    D’Amico G, Ferrario F (1992) Mesangiocapillary glomerulonephritis. J Am Soc Nephrol 2:S159–S166PubMedCrossRefGoogle Scholar
  5. 5.
    Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN (1985) Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 27:436–441PubMedCrossRefGoogle Scholar
  6. 6.
    Orlowski T, Rancewicz Z, Lao M, Juskowa J, Klepacka J, Gradowska L, Morzycka-Michalik M, Glyda J (1988) Long-term immunosuppressive therapy of idiopathic membranoproliferative glomerulonephritis. Klin Wochenschr 66:1019–1023PubMedCrossRefGoogle Scholar
  7. 7.
    Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E (1994) Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 67:59–65PubMedCrossRefGoogle Scholar
  8. 8.
    Haddad M, Lau K, Butani L (2007) Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol 22:1787–1791PubMedCrossRefGoogle Scholar
  9. 9.
    Yi ZW, Dang XQ, He QN, Wu XC, Cao Y, Huang DL, He XJ, Mo SH (2007) Assessment of mycophenolate mofetil for treatment of frequently relapsing nephrotic syndrome in children. Zhong Nan Da Xue Xue Bao Yi Xue Ban 32:938–940PubMedGoogle Scholar
  10. 10.
    Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA (2002) Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098–1114PubMedCrossRefGoogle Scholar
  11. 11.
    Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2000) Efficiency of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Eng J Med 343:1156–1162CrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Sudarsana De
    • 1
  • Dana Al-Nabhani
    • 1
  • Paul Thorner
    • 2
    • 3
    • 4
  • Daniel Cattran
    • 4
    • 5
  • Tino D. Piscione
    • 1
    • 4
  • Christoph Licht
    • 1
    • 4
  1. 1.Division of NephrologyThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Division of PathologyThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoCanada
  4. 4.University of TorontoTorontoCanada
  5. 5.Division of NephrologyToronto General HospitalTorontoCanada

Personalised recommendations